Efficacy of Pembrolizumab in Advanced Melanoma: A Narrative Review

Pembrolizumab has been shown to increase survival in patients with metastatic melanoma. Considering the numerous oncoming studies, we decided to conduct a narrative review of the latest efficacy evidence regarding the use of pembrolizumab, alone or in combination, in patients with metastatic melanom...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2023-08, Vol.24 (15), p.12383
Main Authors: Rizzetto, Giulio, De Simoni, Edoardo, Molinelli, Elisa, Offidani, Annamaria, Simonetti, Oriana
Format: Article
Language:English
Subjects:
advanced melanoma
Care and treatment
Chemotherapy
Clinical trials
Cost analysis
immunotherapy
Ipilimumab
Literature reviews
Melanoma
Metastasis
Patients
pembrolizumab
Review
Skin cancer
Tumors
Vaccines
Vemurafenib
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pembrolizumab has been shown to increase survival in patients with metastatic melanoma. Considering the numerous oncoming studies, we decided to conduct a narrative review of the latest efficacy evidence regarding the use of pembrolizumab, alone or in combination, in patients with metastatic melanoma. A search was conducted in PubMed using "pembrolizumab," and "metastatic melanoma" as keywords, considering studies from 2022 onward. We reviewed pembrolizumab and associations, cost-effectiveness, virus, advanced acral melanoma, long-term outcomes, real-life data, biomarkers, obesity, and vaccines. In conclusion, pembrolizumab is a fundamental option in the therapy of metastatic melanoma. However, a certain group of patients do not respond and, therefore, new combination options need to be evaluated. In particular, the use of vaccines tailored to tumor epitopes could represent a breakthrough in the treatment of resistant forms. Further studies with larger sample numbers are needed to confirm the preliminary results.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms241512383